

SYNTHESIS OF 11- ^3H -ARTEETHER, AN EXPERIMENTAL ANTIMALARIAL DRUG

Yu-Ming Pu and Herman Ziffer*

Laboratory of Chemical Physics

National Institute of Diabetes and Digestive and Kidney Diseases

Bethesda, MD. 20892

SUMMARY


The triphenylphosphine hydrobromide-catalyzed addition of a proton from ethanol to anhydrodihydroartemisinin (**5**) has been employed for the synthesis of **2** and **4**. Use of 1.5 equivalents of EtO^2H or EtO^3H yielded 11- ^2H - or 11- ^3H - β -arteether as the major product.

Keywords: Arteether, Artemisinin, Anhydrodihydroartemisinin, Malaria

INTRODUCTION

Artemisinin (**1**) (the active principle of the medicinal herb, *Artemisia annua*) was isolated by Chinese investigators,¹ who demonstrated that it was effective in treating patients with cerebral malaria, otherwise fatal, as well as those infected with drug-resistant strains of *Plasmodium falciparum*. Their success prompted them and others to prepare a variety of derivatives.¹ One of the most promising derivatives was β -arteether (**2**)² which was several times more active than **1**. However, large doses of **2** were found to cause neurological side effects in dogs and mice.³ Radiolabelled **2** is required to aid in identifying the toxic agent responsible for these side effects. Several preparations of labelled **2** have been described. A ^{14}C labelled sample was prepared from dihydroartemisinin (**3**) and ^{14}C -ethanol,^{4a} and ^3H labelled material was prepared by reduction of the lactone moiety in artemisinin with NaB^3H_4 , followed by etherification.^{4b,c} Since Baker *et al.* demonstrated that O-dealkylation was a major metabolic route of **2**,⁵ it was anticipated that a

labelled ethyl group would rapidly be lost. It was also feared that a ^3H atom on C-12, a labile position, would be lost during *in vivo* metabolism, isolation and purification of metabolites. We previously reported a procedure for preparing 14- ^{2}H -arteether,⁶ however the starting material, a microbial transformation product of arteether, is not readily accessible. This new procedure uses a readily available intermediate to incorporate a tritium label on C-11, where it should be stable to enzymatic degradation and /or exchange under physiological conditions (Scheme1).



Scheme 1: Synthesis of Arteethers from Anhydrodihydroartemisinin (5).

Franck *et al.*⁷ reported a deuterium could be introduced β to the oxygen of an enol ether by employing catalytic quantities of triphenylphosphine hydrobromide (TPP-HBr) and EtO^2H . We investigated TPP-HBr catalyzed additions of alcohols to anhydrodihydroartemisinin (5),⁸ and found that a 1:3 mixture of 4 and 2 was obtained with one to two equivalents of ethanol. This method was utilized to prepare 11- ^{2}H] and [^3H]- β -arteethers.

RESULTS AND DISCUSSION

Anhydrodihydroartemisinin (5) was prepared from 3 by treatment with phosphorous pentoxide.⁹ Reaction of 5 with 1.5 equivalents of EtO^2H in methylene chloride and catalytic quantities of TPP-HBr converted 5 into a 1:3 mixture of 7 and 6. The mixture was separated on a reverse phase

HPLC by eluting with methanol:water (85:15). The deuterium content of **6** was measured by integrating the H-11 signal at $\delta = 2.6$ ppm and the H-12 signal at $\delta = 4.79$ ppm. A chromatographic procedure was sought as an alternative to HPLC in purifying **8**. The reaction mixture of **8** was purified first by TLC with hexane: ethyl acetate (9:1). The resulting product was subjected to a second TLC purification with chloroform: isopropyl ether (97:3). Addition of a deuterium to an enol ether (glucal) occurs *via* an AdE_2 mechanism, *i.e.* a kinetically controlled deuteration; the stereochemistry of the alcohol addition is controlled by a kinetic anomeric effect. Bolitt and Mioskowski¹⁰ have shown that the behavior of TPP-HBr differs from that of Brønsted or Lewis acids. For example, they described the preparation of 2-deoxy-D-glycopyranosides from glucals without Ferrier rearrangement.

EXPERIMENTAL

Materials and Instrumentation. Diethoxydimethylsilane, phosphorous pentoxide, deuterated ethanol (>99.5% D), triphenylphosphine hydrobromide, and absolute ethanol were purchased from Aldrich and used without purification. Tritiated water (specific activity = 1.0 mCi/mL) was from NEN. All other reagents were ACS grade or the highest quality material available. Dried dichloromethane was prepared by refluxing in P_2O_5 for a few hours and distilled off before use. $^1\text{H-NMR}$ was run at 300 MHz and $^{13}\text{C-NMR}$ at 75 MHz on a Varian Gemini 300. FT-IR was measured on Bio-Rad FTS-45, and CI-MS on a Finnigen 4600 Mass Spectrometer. Elemental analysis was performed by Galbraith Laboratory, Inc., Tennessee. Radioactivity was measured by a Beckman LS3800 liquid scintillator.

Radioactive Ethanol ($\text{CH}_3\text{CH}_2\text{O}^3\text{H}$).¹¹ To a mixture of diethoxydimethylsilane (7.4g, 0.05 mole) and 1.0 g of radioactive water (NEN, 1.0 mCi/mL, *e.g.* 0.018 mCi/ mmole) was added 50 μL of concentrated aqueous HCl. The reaction mixture was stirred at rt. for 15 min. and the ethanol distilled from the flask (4.6 g, 0.010 mCi/ mmole).

Anhydrodihydroartemisinin (5**).** To a solution of dihydroartemisinin (1.5 g, 5.28 mmole) in 200 mL of dried CH_2Cl_2 was added 1.5 g of P_2O_5 powder at rt. The reaction mixture was stirred for 30 min., and poured into water. The organic layer was separated, washed with 1% aqueous NaHCO_3 , dried, filtered, and concentrated. The crude product was purified by flash chromatography (Hexane:ether=15:1) to afford 1.1 g of **5** (80%). mp 94-96 °C (Lit.⁹ mp 95-97°C); $[\alpha]_D^{25} = +130^\circ$ (*c* 0.85, CHCl_3), $+120^\circ$ (*c* 0.85, EtOH); $^1\text{H-NMR}$ (CDCl_3) δ 6.17 (1H, s,

C_{12} -CH=), 5.51 (1H, s, C_5 -CH), 2.38 (1H, ddd, $J=13.9, 13.9, 3.9$ Hz, C_3 -CH $_{\alpha}$ H), 2.3-1.0 (10H, overlapping, carbon skeleton protons), 1.57 (3H, s, C_{13} -CH $_3$), 1.41(3H, s, C_{15} -CH $_3$), 0.96 (3H, d, $J=5.1$ Hz, C_{14} -CH $_3$).

β -Arteether (2) and 11-*epi*- β -Arteether (4).

In a 100 mL round bottom flask were placed anhydrodihydroartemisinin (318 mg, 1.2 mmole), triphenylphosphine hydrobromide (21.0 mg, 0.06 mmole), absolute ethanol (0.11 mL, 1.8 mmole) and 36 mL of dried CH $_2$ Cl $_2$. The reaction mixture was stirred at rt. for 3 h and poured into water. The organic phase was washed with 1% aqueous NaHCO $_3$, dried, filtered and concentrated. The crude product was purified by flash chromatography (hexane:ethyl acetate = 94:6) to afford a mixture of β -arteether (2) and 11-*epi*- β -arteether (4) (165 mg, 3:1). The mixture was separated by reverse phase HPLC (methanol:water =85:15) to provide 110 mg of 2 (29%) and 34 mg of 4 (9%).

2: mp 81-83 °C (Lit.² 80-82 °C); $[\alpha]_D = +150^\circ$ (*c* 0.50, CHCl $_3$), $+140^\circ$ (*c* 0.50, EtOH). 1 H- and 13 C-NMR spectral data were in accord with those reported.²

4: mp 60-62 °C; $[\alpha]_D = +140^\circ$ (*c* 0.50, CHCl $_3$), $+130^\circ$ (*c* 0.50, EtOH), 1 H-NMR (CDCl $_3$) δ 5.46 (1H,s, C_5 -CH), 4.98 (1H,d, $J=5.3$ Hz, C_{12} -CH), 3.85, 3.51 (2H, m C_{16} -CH $_2$), 2.24 (1H, ddd, $J=13.9, 13.9, 3.9$ Hz, C_3 -CH $_{\alpha}$ H), 2.02 (1H, ddd, $J=13.9, 3.9, 3.9$ Hz, C_3 -CHH β), 2.0-1.0 (10H, overlapping, carbon skeleton protons), 1.41 (3H,s, C_{15} -CH $_3$), 1.24 (3H, t, $J=7.0$ Hz, C_{17} -CH $_3$), 1.18 (3H,d, $J=7.0$ Hz, C_{13} -CH $_3$), 0.95 (3H, d, $J=6.1$ Hz, C_{14} -CH $_3$); 13 C-NMR (Table1); FT-IR (KBr) 2960, 1050, 980, 925 cm^{-1} ; CI-MS (NH $_3$): 330 [(M+NH $_4$) $^+$, 5 %], 284 [(M+NH $_4$) $^+$ -CH $_3$ CH $_2$ OH, 28%], 267 [(M+NH $_4$) $^+$ -CH $_3$ CH $_2$ OH - NH $_3$, 100%]; Anal. calcd for C $_{17}$ H $_{28}$ O $_5$; C, 65.36; H, 9.03. Found C, 65.33; H, 9.05.

11- ^{2}H]- β -Arteether (6) and 11- ^{2}H]-11-*epi*- β -Arteether (7).

These compounds were prepared using deuterated ethanol and purified as described above.

6 (30%): mp 81-83 °C; $[\alpha]_D = +150^\circ$ (*c* 0.50, CHCl $_3$), $+140^\circ$ (*c* 0.50, EtOH), 1 H-NMR (CDCl $_3$) δ 5.41 (1H, s, C_5 -CH), 4.79 (1H, s, C_{12} -CH), 3.83, 3.43 (2H, m, C_{16} -CH $_2$), 2.37 (1H, ddd, $J=14.1, 14.1, 3.9$ Hz, C_3 -CH $_{\alpha}$ H), 2.05 (1H, ddd, $J=14.1, 3.9, 3.9$ Hz, C_3 -CHH β),

2.0-1.0 (9H, overlapping, carbon skeleton protons), 1.44 (3H, s, C₁₅), 1.18 (3H, t, J=7.0 Hz, C₁₇-CH₃), 0.95 (3H, d, J=6.1Hz, C₁₄-CH₃), 0.90 (3H,s, C₁₃-CH₃); ¹³C-NMR (Table 1); CI-MS (NH₃): 331 [(M+NH₄)⁺, 10%], 284 [(M+NH₄)⁺-CH₃CH₂OD, 28%], 267 [(M+NH₄)⁺-CH₃CH₂OD- NH₃, 100%]; Anal. calcd for C₁₇H₂₇DO₅; C, 65.15; H, 8.68. Found C, 65.27; H, 8.88.

7 (10%): mp=60-62°C, [α]_D=+140° (c 0.50, CHCl₃), +130° (c 0.50, EtOH); ¹H-NMR (CDCl₃) δ 5.46 (1H, s, C₅-CH), 4.98 (1H, s, C₁₂-CH), 3.92, 3.58 (2H, m, C₁₆-CH₂), 2.30 (1H, ddd, J=14.0, 14.0, 3.9 Hz, C₃-CH_αH), 2.03(1H, ddd, J=14.0, 3.9, 3.9 Hz, C₃-CHH_β), 2.0-1.0 (9H, overlapping, carbon skeleton protons), 1.42 (3H, s, C₁₅-CH₃), 1.24 (3H, t, J=7.1 Hz, C₁₇-CH₃), 1.17 (3H, s, C₁₃-CH₃), 0.95 (3H, d, J=5.8 Hz, C₁₄-CH₃); ¹³C-NMR (Table 1); FT-IR (KBr) 2960, 1050, 988, 924 cm⁻¹; CI-MS (NH₃): 331[(M+NH₄)⁺, 10%], 284 [(M+NH₄)⁺-CH₃CH₂OD, 40%], 267 [(M+NH₄)⁺-CH₃CH₂OD-NH₃, 100%]; Anal. calcd for C₁₇H₂₇DO₅; C, 65.15; H, 8.68. Found C, 65.30; H, 8.90.

Radioactive 11-^[3H]-β-Arteether (8). The compound was prepared as described above starting from the radioactive ethanol (0.010 mCi/mmol). The purification was modified as

Table 1 : ¹³C-MNR Assignment of Arteethers

Carbon #	2	6	4	7
1	52.81	52.63	51.88	51.85
2	24.80	24.78	24.80	24.78
3	36.60	36.53	36.60	36.59
4	104.0	104.0	102.9	102.8
5	87.90	87.86	89.16	89.14
6	81.15	81.16	81.70	81.14
7	44.65	44.48	46.69	46.59
8	24.63	24.51	31.69	31.59
9	34.78	34.73	34.49	34.47
10	37.56	37.50	37.35	37.34
11	31.01	30.9(wk)	40.02	40.0(wk)
12	101.7	101.6	102.3	102.3
13	13.14	13.01	19.55	19.42
14	20.36	20.46	20.14	20.12
15	26.31	26.30	26.04	26.03
16	63.78	63.76	64.18	64.16
17	15.31	15.31	15.31	15.29

followed: The crude product was first purified by preparative TLC (Analtech, 20x20 cm, 500 μ m thickness) with hexane : ethyl acetate (9:1) and rechromatographed on TLC with CHCl_3 : isopropyl ether (97:3) to give **8** (0.0038 mCi/mmole).

REFERENCES

1. (a) Klayman D.L. - *Science* **228**: 1049 (1985).
(b) Luo X-D and Shen C-C. - *Med. Res. Rev.* **7**: 29 (1987).
2. Brossi A., Venugopalan B., Gerpe L.D., Yeh H.J.C., Flippen-Anderson J.L., Buchs P., Luo X-D., Milhous W. and Peters W. - *J. Med. Chem.* **31**: 645 (1988).
3. Brewer T.G., Grate S.J., Peggins J.O., Petras P.J., Levine B.S., Heiffer M.H. and Schuster B.G. - Abs. of the 41ST Annual Meeting of the Amer. Soc. of Trop. Med. and Hyg., Seattle, Washington, Nov. 15-19, 93 (1992).
4. (a) Yang H.Y., Jiang J.K. and Zeng Y-L. - *Yiyao Gongje* **12**: 1 (1981).
(b) Gu H.M., Warhurst D.C. and Peters W. - *Trans. R. Soc. Trop. Med. Hyg.* **788**: 265 (1984).
(c) Ding S.F., and Yi M.G. - *Bull. Chin. Mater. Med.* **6**: 25 (1981).
5. Chi H.T., Ramu K., Baker J.K., Hufford C.D., Lee I-S., Zeng Y-L. and McChesney J.D. *Biol. Mass Spectrom.* **20**: 609 (1991).
6. Hu Y. and Ziffer H. - *J. Labelled Compd. and Radiopharm.* **29**: 1293 (1991).
7. Kaila N., Blumenstein M., Bielawska H. and Franck R.W. - *J. Org. Chem.* **57**: 4576 (1992).
8. Pu Y.-M. and Ziffer H. - "Synthesis and Antimalarial Activities of a series of ethers of of 11-epi-dihydroartemisinin ", manuscript in preparation.
9. Petrov O. and Ognyanov I. - *Collect. Czech. Chem. Commun.* **56**: 1037 (1991).
10. Bolitt V. and Mioskowski C. - *J. Org. Chem.* **55**: 5812 (1990).
11. Greive W.H. and Sporek K.F. - *J. Chem. Educ.* **43**: 381 (1966).